Nanobiotix will present results from clinical trials of its NBTXR3 radioenhancer at the 2021 American Society for Radiation Oncology (ASTRO) meeting, which will be held October 24-27 in Chicago.
NBTXR3 is made of functionalized hafnium oxide nanoparticles and is administered via a one-time intratumoral injection. It is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy.
The product will be highlighted in five ASTRO presentations, including a poster presentation scheduled for October 26 by Dr. Christophe Le Tourneau, PhD, of the Curie Institute in Paris. Le Tourneau will share the first overall survival data from a phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC).
NBTXR3 is being evaluated in locally advanced HNSCC as the primary development pathway. The company said it believes NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
In 2019, Nanobiotix entered into a broad, comprehensive clinical research collaboration with the University of Texas MD Anderson Cancer Center to sponsor clinical trials to evaluate NBTXR3 across tumor types and therapeutic combinations.
